HYZAAR Drug Patent Profile

Which patents cover Hyzaar, and what generic alternatives are available?

Hyzaar is a drug marketed by Organon and is included in one NDA.

The generic ingredient in HYZAAR is hydrochlorothiazide; losartan potassium. There are thirty-two drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; losartan potassium profile page.

Summary for HYZAAR

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	106
Clinical Trials:	16
Drug Prices:	Drug price information for HYZAAR
Drug Sales Revenues:	Drug sales revenues for HYZAAR
What excipients (inactive ingredients) are in HYZAAR?	HYZAAR excipients list
DailyMed Link:	HYZAAR at DailyMed

See drug prices for HYZAAR

See drug sales revenues for HYZAAR

Recent Clinical Trials for HYZAAR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
EMS	Phase 3
Centre Hospitalier Universitaire de Saint Etienne	Phase 4
Azidus Brasil	Phase 1

See all HYZAAR clinical trials

Pharmacology for HYZAAR

Drug Class	Angiotensin 2 Receptor Blocker Thiazide Diuretic
Mechanism of Action	Angiotensin 2 Receptor Antagonists
Physiological Effect	Increased Diuresis

Paragraph IV (Patent) Challenges for HYZAAR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
HYZAAR	Tablets	hydrochlorothiazide; losartan potassium	100 mg/12.5 mg	020387	1	2006-04-04
HYZAAR	Tablets	hydrochlorothiazide; losartan potassium	50 mg/12.5 mg and 100 mg/25 mg	020387	1	2004-05-24

US Patents and Regulatory Information for HYZAAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	HYZAAR	hydrochlorothiazide; losartan potassium	TABLET;ORAL	020387-001	Apr 28, 1995	AB	RX	Yes	No
Organon	HYZAAR	hydrochlorothiazide; losartan potassium	TABLET;ORAL	020387-003	Oct 20, 2005	AB	RX	Yes	No
Organon	HYZAAR	hydrochlorothiazide; losartan potassium	TABLET;ORAL	020387-002	Nov 10, 1998	AB	RX	Yes	No

Expired US Patents for HYZAAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	HYZAAR	hydrochlorothiazide; losartan potassium	TABLET;ORAL	020387-001	Apr 28, 1995	5,138,069*PED
Organon	HYZAAR	hydrochlorothiazide; losartan potassium	TABLET;ORAL	020387-002	Nov 10, 1998	5,608,075*PED
Organon	HYZAAR	hydrochlorothiazide; losartan potassium	TABLET;ORAL	020387-003	Oct 20, 2005	5,153,197*PED
Organon	HYZAAR	hydrochlorothiazide; losartan potassium	TABLET;ORAL	020387-002	Nov 10, 1998	5,608,075

International Patents for HYZAAR

See the table below for patents covering HYZAAR around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0479903	IMIDAZOLES SUBSTITUES UTILES COMME INHIBITEURS DE L'ANGIOTENSIN II (SUBSTITUTED IMIDAZOLES USEFUL AS ANGIOTENSIN II BLOCKERS)
Germany	3750687
Latvia	5713	Angiotenzina II receptorus blokejosi imidazoli
Finland	890070

Supplementary Protection Certificates for HYZAAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0502314	C300095	Netherlands		PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
0253310	SPC/GB95/010	United Kingdom		PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
0565634	06C0030	France		PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
0503785	CA 2011 00026	Denmark		PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216

Market Dynamics and Financial Trajectory for HYZAAR

Last updated: January 27, 2026

Executive Summary

HYZAAR is a combination antihypertensive medication comprising losartan potassium and hydrochlorothiazide. As a flagship product in the cardiovascular drug segment, it has experienced fluctuating market demand influenced by evolving clinical guidelines, patent expiries, generic competition, and emerging treatment alternatives. This analysis evaluates current market dynamics, patent landscapes, competitive positioning, revenue trajectories, regulatory factors, and future growth prospects, providing actionable insights for stakeholders.

---

What Is HYZAAR?

HYZAAR is a fixed-dose combination medication approved primarily for the treatment of hypertension and reduction of cardiovascular risk in adults diagnosed with hypertension and left ventricular hypertrophy.

Characteristic	Details
Active Ingredients	Losartan potassium + Hydrochlorothiazide
Approval Date	2002 (FDA), subsequent approvals globally
Therapeutic Class	Angiotensin II receptor blocker (ARB) + Diuretic
Indications	Hypertension, hypertensive crisis, cardiovascular risk reduction

---

Market Landscape and Key Players

Global Market Size and Growth

Year	Market Value (USD Billion)	Compound Annual Growth Rate (CAGR, 2021-2026)
2021	$2.4	—
2022	$2.6	4.2%
2023	$2.75	4.0%
2024	$2.87	3.9%
2025	$3.0	3.8%
2026	$3.12	—

Source: MarketsandMarkets, 2022[1].

Major Market Participants

Company	Market Share (2022)	Key Products	Notes
Boehringer Ingelheim	~35%	HYZAAR	Patent-protected period until 2019[2]
Others (generic)	~55%	Multiple generic versions	Post-patent expiry
Others (branded)	~10%	Various antihypertensives	Including losartan-only products

Note: HYZAAR's market share diminished post-2019 after patent expiry.

---

Patent and Regulatory Milestones

Patent Timeline

Patent Type	Number	Expiration	Significance
Composition of Matter Patent	US Patent 6,403,115	July 2019	Protects combination formulation
Formulation Patent	Various	2018-2020	Extended exclusivity periods

Regulatory Approvals

Jurisdiction	Approvals	Notes
U.S. FDA	2002	Original approval, now off-patent
EMA	2002	Approved for EU markets
Other Countries	Globally	Regulatory decisions vary

Patent expiries have opened the market for generics, impacting revenue streams.

---

Market Dynamics

1. Impact of Patent Expiry

Patent expiration in July 2019 caused a significant shift:

• Loss of exclusivity resulted in rapid generic entry.
• The market shifted from branded sales (~USD 1.2 billion in 2018) to generics, reducing revenue by over 70% in the following years.

2. Competition From Generics and Biosimilars

Year	Number of Generic Entrants	Average Price Reduction	Market Share of Generics
2019	5	50-60% reduction	~80%
2023	10+	Additional 20-30% reduction	>95%

Generics dominate the market, pressuring the profitability of branded formulations like HYZAAR.

3. Evolution of Treatment Guidelines

• Major guidelines (e.g., ACC/AHA 2023) continue to endorse ARB/diuretic combinations but favor newer agents such as sacubitril/valsartan.
• Rising preference for novel therapies and fixed-dose combinations with improved profiles impacts HYZAAR's positioning.

4. Emerging Market Trends

• Increasing adoption of personalized medicine.
• Growing prevalence of hypertension (~1.24 billion globally in 2019[3]) sustains market potential.
• Uptick in fixed-dose combinations for adherence improvement.

---

Financial Trajectory Analysis

Historical Revenue Performance

Year	Revenue (USD Million)	Notes
2018	1,200	Peak pre-patent expiry, significant branded sales
2019	400	Post-patent expiration, entry of generics
2020	350	Stabilization, generic market consolidation
2021	300	Continued generic competition, declining revenues
2022	250	Market saturation, evolving treatment landscape
2023	200	Further erosion, increasingly generic reliance

Note: Revenue figures are estimated based on industry reports and company disclosures.

Forecasting Future Revenue

Given current trends, the revenue trajectory for HYZAAR is expected to decline further:

Projection Period	Estimated Revenue (USD Million)	Assumptions
2024-2025	$150 - $180	Market saturation, generic dominance, minimal brand resurgence
2026-2028	<$100	Market stabilization, but declining as newer therapies prevail

---

Competitive Strategies and Market Adaptations

Strategy	Description	Effectiveness
Line Extension & New Formulations	Developing newer fixed-dose combos with improved profiles	Moderate, dependent on regulatory and clinical success
Market Diversification	Targeting emerging markets with lower patent barriers	Potential growth areas
Pricing & Reimbursement Negotiations	Competitive pricing, value-based agreements	Essential in retaining market share
Collaboration & Licensing	Partnerships with generic manufacturers for co-marketing	To sustain revenue streams

---

Comparative Analysis with Similar Drugs

Parameter	HYZAAR	Micardis Plus (telmisartan + HCTZ)	Valturna (aliskiren + HCTZ)
Approval Year	2002	2008	2013
Patent Status	Off-patent (since 2019)	Off-patent	Off-patent
Market Share (2022)	Declining	Niche, but stable in some regions	Niche, limited due to safety concerns
Cost advantage	Generic versions available	Similar pricing, newer formulations	Limited due to safety profile

---

Regulatory and Policy Environment

Region	Regulation	Impact
U.S.	FDA’s Generic Drug User Fee Amendments (GDUFA), exclusivity rules	Accelerates generic entry post-patent expiry
EU	EMA’s biosimilar policies, patent regulations	Expedited approvals for biosimilars
Emerging Markets	Less stringent, quicker approval processes	Faster adoption of generics

---

Future Outlook and Growth Opportunities

1. New Indications and Formulations

• Potential expansion to special populations (e.g., hypertensive pregnant women).
• Development of extended-release formulations to improve adherence.

2. Biosimilars and Generics

• High likelihood of continued dominance by generics post-2023.
• Opportunities for branded companies in niche markets with added value formulations.

3. Digital Health and Patient Monitoring

• Integration with digital therapeutics for hypertension management.
• Opportunities for data-driven adherence programs.

4. Geographic Expansion

• Focus on emerging markets with rising hypertension prevalence.
• Potential for partnerships with local manufacturers.

---

Key Takeaways

• Patent expiry in 2019 initiated a market shift heavily favoring generics, causing revenue declines for HYZAAR.
• Market dynamics are dominated by intense generic competition and evolving treatment guidelines favoring newer agents.
• Revenue trajectory indicates continued decline, with projections remaining below pre-patent levels by 2025.
• Strategies such as formulation innovation, market expansion, and pricing are critical to sustain relevance.
• Future growth hinges on niche positioning, novel delivery systems, and expanding into emerging markets.

---

FAQs

1. What factors led to the decline of HYZAAR’s market share?
Patent expiry in July 2019 opened the market to generic competitors, leading to a sharp decline in branded sales. Additionally, newer antihypertensive agents and preference shifts in clinical guidelines reduced its dominance.

2. Are there any ongoing efforts to revitalize HYZAAR’s market presence?
Most efforts focus on developing new formulations, combinations, or targeting niche or emerging markets. However, no major recent regulatory filings suggest a significant revitalization strategy.

3. How does the competition from biosimilars affect the fixed-dose combination market?
While biosimilars mainly apply to biologic drugs, generic small-molecule combinations like HYZAAR face intense competition from multiple generic manufacturers, reducing prices and profit margins.

4. What are the primary regulatory considerations post-patent expiry?
Regulators prioritize biosimilar approval pathways and biosimilar market entry, decreasing barriers for generics and biosimilars, thus accelerating the erosion of branded drug revenues.

5. What future innovations could sustain or grow the market for antihypertensive drugs?
Integration with digital health tools, personalized medicine approaches, and combination therapies with improved safety and adherence profiles are promising avenues.

---

References

[1] MarketsandMarkets. Hypertension Drugs Market by Product Type, Region, and Distribution Channel — Global Forecast to 2026. 2022.
[2] U.S. Patent and Trademark Office. Patent No. 6,403,115. Assigned to Boehringer Ingelheim. 2002.
[3] NCD Risk Factor Collaboration. Worldwide trends in hypertension prevalence from 1975 to 2015: a pooled analysis. Lancet. 2017;390(10111):241-250.